Renal Cell Carcinoma
Renal Cell Carcinoma

Translational Biology, Personalized Medicine, and Novel Therapeutic Targets
Preface

Tremendous strides have been made in recent years in unraveling the aberrant biology driving renal carcinomas. These discoveries have led to unparalleled shifts in the treatment paradigm of this once devastating disease, historically known for its unrelenting progression of metastatic disease and high incidence of drug resistance and fatality. Rapidly emerging new therapeutic strategies that have the ability to neutralize this cancer have now engendered hope and optimism. In many instances, the speed of advances in clinical management has outpaced the biology, and observations made in the clinic using new therapeutics have fueled scientific discovery. In this way, renal cell carcinoma has truly served as a paradigm tumor type in the rapid flux of discovery from bench to bedside and back to the bench.

This textbook reviews and examines this enormously productive period with chapters touching on every major topic area in the modern era of renal carcinoma biology and treatment. Beginning with the discovery of the von Hippel Lindau (VHL) gene in 1993, we now understand on a more fundamental level the association of VHL mutation and the resultant HIF family stabilization as well as the intimate relationship this axis plays in the development of clear cell renal cell carcinoma. The unique and intricate genetics of this cancer are highly distinct from most other tumors, and the advances made in this cancer beyond VHL biology have been intrinsically driven by discoveries from familial renal cell carcinomas linked with newer large-scale genomic efforts in sporadic disease. The remarkable parallels of sporadic and familial diseases have enabled the elucidation of critical pathways in the renal tumorigenic process. These genetic findings fuel strategies to analyze and define sporadic tumors for greater accuracy in prognosis and prediction of response to therapy, the latest of which will be detailed in this text. Completing the circle, major new therapeutic strategies harness these biological discoveries, in particular angiogenic, energy metabolism, chromatin remodeling, tumor microenvironment, and classical signaling pathways. Many of these therapies have moved beyond management of metastatic disease to arenas in combination with surgical approach to advance the opportunities for durable remission or cure. This text will bring all of these avenues of investigation together for readers interested in understanding the
dynamics of this field in the last decade and anticipating a continued steep trajectory in advancements toward the cure of this disease in its many manifestations.

The field does continue to evolve at an enormously rapid pace. In addition to placing each of these major advances in historical context, the chapters in this textbook take a critical look forward to consider the future advances in each topic. The goal of this textbook is to educate the reader regarding the state of the art in renal cancer biology and therapeutic strategies as well as to engage readers as participants in an ongoing and exciting period of discovery and translation to advance the care of patients with renal cell carcinoma.

Los Angeles, CA, USA  Robert A. Figlin, M.D., F.A.C.P.
Chapel Hill, NC, USA  W. Kimryn Rathmell, M.D., Ph.D.
Cleveland, OH, USA  Brian I. Rini, M.D., F.A.C.P.
## Contents

### Part I  Biology of Renal Cell Carcinoma

1  The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies ........................................... 3  
   Laura S. Schmidt, Ramaprasad Srinivasan, and W. Marston Linehan

2  Molecular Biology of Clear Cell Renal Carcinoma .............. 27  
   William G. Kaelin Jr.

3  HIF Biology in RCC: Implications for Signaling, Disease Progression, and Treatment ................................. 49  
   W. Kimryn Rathmell

4  Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC ......................................................... 69  
   Brittany Bahamon and Sabina Signoretti

5  Molecular Characterization of Renal Cell Carcinoma ........... 91  
   Bin Tean Teh, Leslie J. Farber, and Kyle Furge

### Part II  Current and Future Molecular Targets for RCC

6  Targeting the VEGF Pathway in Renal Cell Carcinoma ........ 115  
   Cristina Suarez and Brian I. Rini

7  Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma ....................... 135  
   C. Lance Cowey and Thomas E. Hutson

8  Research Translation and Personalized Medicine .................. 161  
   James Brugarolas
9 Epigenetic Targeting and Histone Deacetylase Inhibition in RCC ................................................................. 193
  Swathi Ramakrishnan and Roberto Pili

10 C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma ......................................................... 213
  Hema Vankayala, Patricia LoRusso, and Ulka Vaishampayan

11 Characterizing and Modulating the Tumor Microenvironment in Renal Cell Carcinoma: Potential Therapeutic Strategies ................................................................. 239
  Sumanta Kumar Pal, Karen Reckamp, Hua Yu, and Robert A. Figlin

12 Carbonic Anhydrase IX: Its Role as a Biomarker, Diagnostic, and Therapeutic Target in Renal Cell Carcinoma .................................................................................. 253
  E. Oosterwijk, A.B. Stillebroer, and P.F.A. Mulders

13 Presurgical Therapy for Renal Cell Carcinoma and Implications for Window-of-Opportunity Trials .................. 271
  Hyung L. Kim, Edwin M. Posadas, and Robert A. Figlin

14 Mechanisms of Resistance to VEGF-Directed Therapy and Implications for Future Trial Design .................. 283
  James W. Mier

15 Vaccine-Based Immunotherapy and Targeting the Tumor Microenvironment in Renal Cell Carcinoma .......... 305
  Johannes Vieweg

Index .......................................................................................................................................................... 323
 Contributors

Brittany Bahamon, B.S.  Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

James Brugarolas, M.D., Ph.D.  Oncology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

Department of Developmental Biology, University of Texas Southwestern Medical Center, Dallas, TX, US

C. Lance Cowey, M.D.  Genitourinary Oncology Program, Baylor-Sammons Cancer Center, Texas Oncology, PA, Dallas, TX, USA

Leslie J. Farber, Ph.D.  NCCS-VARI Translational Research Laboratory, National Cancer Centre and Duke-NUS Graduate Medical School, Singapore

Robert A. Figlin, M.D., F.A.C.P.  Professor of Medicine and Biomedical Sciences, Director, Division of Hematology Oncology, Department of Medicine, Cedars-Sinai Medical Center, Associate Director for Academic Programs, Samuel Oschin Comprehensive Cancer Institute, Professor Emeritus of Medicine and Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Kyle Furge, Ph.D.  Van Andel Research Institute, Grand Rapids, MI, USA

Thomas E. Hutson, D.O., Pharm.D., F.A.C.P.  Genitourinary Oncology Program, Baylor-Sammons Cancer Center, Texas Oncology, PA, Dallas, TX, USA

William G. Kaelin Jr., M.D.  Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, USA

Howard Hughes Medical Institute, Chevy Chase, MD, USA
Hyung L. Kim, M.D. Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA

W. Marston Linehan, M.D. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Patricia LoRusso, D.O. Karmanos Cancer Institute, Detroit, MI, USA

James W. Mier, M.D. Division of Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA

P.F.A. Mulders, M.D., Ph.D. Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

E. Oosterwijk, Ph.D. Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Sumanta Kumar Pal, M.D. Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Roberto Pili, M.D. Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA

Edwin M. Posadas, M.D. Division of Hematology/Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Swathi Ramakrishnan, M.S. Genitourinary Program, Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, NY, USA

W. Kimryn Rathmell, M.D., Ph.D. UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Karen Reckamp, M.D. Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Brian I. Rini, M.D. Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological and Kidney Institute, Cleveland, OH, USA

Laura S. Schmidt, Ph.D. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Basic Science Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD, USA

Sabina Signoretti, M.D. Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Ramaprasad Srinivasan, M.D., Ph.D. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
A.B. Stillebroer, M.D.  Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Cristina Suarez, M.D.  Department of Medical Oncology, Hospital General Vall d’Hebron, Barcelona, Spain

Bin Tean Teh, M.D., Ph.D.  Van Andel Research Institute, Grand Rapids, MI, USA

Ulka Vaishampayan, M.D.  Hudson Webber Cancer Research Center, Detroit, MI, USA

Hema Vankayala, M.D.  Hudson Webber Cancer Research Center, Division of Hematology/Oncology, Detroit, MI, USA

Johannes Vieweg, M.D., F.A.C.S.  Department of Urology and Prostate Disease Center, College of Medicine, University of Florida, Gainesville, FL, USA

Hua Yu, Ph.D.  Cancer Immunotherapeutics Program, City of Hope Comprehensive Cancer Center, Duarte, CA, USA